Demographics

View past meeting statistics and demographic information for the Annual Meeting.

2016 Registration Numbers

  • Total—38,800
  • Professionals—31,900
  • Exhibitors—5,180
  • Spouse, Guest, Media—1,720
  • Domestic Attendees—52%
  • International Attendees—48%

Top 10 Countries in Attendance in 2016

  • United States—16,520
  • Germany—1,389
  • Japan—1,342
  • France—1,196
  • United Kingdom—1,021
  • China—919
  • Canada—885
  • Brazil—765
  • Spain—667
  • Switzerland—619

Primary Professional Role in 2016

Primary Professional Role Percentage of Attendees who Responded
Physician 41%
Other 34%
Researcher 9%
Marketing Representative 4%
Business Administrator 3%
Pharmacist 2%
Sales Representative 2%

Biostatistician / Epidemiologist

1%
Student 1%
Office Manager 1%
Nurse 1%

Financial Service Representative

1%

Attendees were allowed to choose only one answer. Responded— 31,150 (98%). No Response—750 (2%). Total—31,900             

Board Certification or International Equivalent in 2016

Board Certification or International Equivalent Percentage of Attendees who Responded
Medical Oncology 37%
Not Applicable 28%
Internal Medicine 22%
Hematology 15%
Other 6%
Oncology Pharmacy 5%
Laboratory Research 5%
Pharmacology (Clinical) 4%
Surgery (including Surgical Oncology and Surgical Specialties) 3%
Biostatistics / Epidemiology 3%
Radiation Oncology 3%
Gynecologic Oncology 3%
Pediatics (including Pediatric Oncology and Pediatric Specialties) 2%
Gastroenterology 2%
Allied Health (e.g. Psychology, Physical Therapy, Social Work, etc.) 2%
Oncology Nursing 2%
Pathology 2%
Urology, Urologic Oncology 2%
Health Care Administration 1%
Neurology 1%
Hospice and Palliative Medicine 1%
Physician's Assistant 1%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded—20,660 (65%). No Response—11,240 (35%). Totals—31,900 (100%)

Primary Interest in 2016

Primary Interest Percentage of Attendees who Responded
Clinical Trials 37%
Breast Cancer 34%
Lung Cancer 32%
Gastrointestinal (Colorectal Cancer) 20%
Developmental Therapeutics 20%
Tumor Biology 17%
Lymphoma and CLL 16%
Cancer Prevention, Genetics, and Epidemiology 13%
Gastrointestinal (Noncolorectal Cancer) 13%
Melanoma / Skin Cancers 12%
Leukemia, Myelodysplasia, and Transplantation 12%
Genitourinary (Prostate) Cancer 11%
Head and Neck Cancer 10%
Gynecologic Oncology 9%
Plasma Cell 7%
Genitourinary (Nonprostate) Cancer 7%
Professional Development 7%
Patient and Survivor Care 6%
Health Services Research 5%
Sarcoma / Bone and Soft Tissue Cancers 5%
Care Delivery and Practice Management 4%
Central Nervous System Tumors 4%
Pediatric Cancer 4%
Disparaties / Access to Care 4%
Value 3%
Other 3%
Ethics 2%
Geriatric Oncology 2%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded— 20,140 (63%). No Response—11,760 (37%). Totals—31,900     

2016 Abstract Statistics 

Abstracts Submitted: 5,817

  • 5,225 Regular submissions
  • 60 Late-breaking data submissions
  • 532 Trials in Progress submissions

Accepted for Presentation: 2,463 (42%), ePublication Only: 2,777 (48%), Rejected or Withdrawn before Review: 577 (10%).

Abstract Submissions by Track in 2016

Track Number of Submissions
Breast Cancer—HER2/ER 252
Breast Cancer—Triple Negative/Cytotoxics/Local Therapy 197
Cancer Prevention, Hereditary Genetics, and Epidemiology 241
Central Nervous System Tumors 152
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics 307
Developmental Therapeutics—Immunotherapy 246
Gastrointestinal (Colorectal) Cancer 356
Gastrointestinal (Noncolorectal) Cancer 468
Genitourinary (Nonprostate) Cancer 271
Genitourinary (Prostate) Cancer 248
Gynecologic Cancer 266
Head and Neck Cancer 185
Health Services Research and Quality of Care 459
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant 154
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia 182
Hematologic Malignancies—Plasma Cell Dyscrasia 79
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 196
Lung Cancer—Non-Small Cell Metastatic 309
Melanoma/Skin Cancers 197
Patient and Survivor Care 380
Pediatric Oncology 106
Sarcoma 136
Tumor Biology 430

*Submissions were received from 82 countries in 2016. There were 2,967 domestic submissions (51%) and 2,850 international (49%).

Top International Countries By Abstract Submission in 2016

China: 279
Japan: 270
France: 245
Canada: 242
Germany: 199
U.K.: 195
Italy: 186
Spain: 155

Clinical Trials and Funding

1,995 Abstracts Reported “Yes” to Clinical Trial

  • 1,139 Funded by a Pharmaceutical/Biotech Company
  • 542 Funded by Academic Institution or International Federal Agencies
  • 168 Funded by a Foundation
  • 146 Funded by National Institutes of Health (NIH)